IN8bio
INAB
13 hedge funds and large institutions have $7.8M invested in IN8bio in 2021 Q4 according to their latest regulatory filings, with 3 funds opening new positions, 5 increasing their positions, 2 reducing their positions, and 3 closing their positions.
150% more repeat investments, than reductions
Existing positions increased: 5 | Existing positions reduced: 2
0% more funds holding
Funds holding: 13 → 13 (0)
0% more ownership
Funds ownership: 0.32% → 0.32% (+0%)
0% more first-time investments, than exits
New positions opened: 3 | Existing positions closed: 3
36% less capital invested
Capital invested by funds: $12.2M → $7.8M (-$4.39M)
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Ensign Peak Advisors
Salt Lake City,
Utah
|
+$461K |
| 2 |
SPC
Sigma Planning Corp
Ann Arbor,
Michigan
|
+$188K |
| 3 |
VC
Voss Capital
Houston,
Texas
|
+$139K |
| 4 |
HighTower Advisors
Chicago,
Illinois
|
+$65.7K |
| 5 |
Vanguard Group
Malvern,
Pennsylvania
|
+$46.8K |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Tudor Investment Corp
Stamford,
Connecticut
|
-$434K |
| 2 |
RCG
Rock Creek Group
Washington,
District of Columbia
|
-$292K |
| 3 |
Millennium Management
New York
|
-$175K |
| 4 |
NCM
Nantahala Capital Management
New Canaan,
Connecticut
|
-$12K |
| 5 |
UBS Group
Zurich,
Switzerland
|
-$11.3K |
| Name | Holding | Trade Value |
Shares Change |
Change in Stake |
|
|---|---|---|---|---|---|
1
Capital World Investors
Los Angeles,
California
| $3.51M | – | – | – |
|
|
NCM
2
Nantahala Capital Management
New Canaan,
Connecticut
| $1.64M | -$12K | -61 | -0.5% |
|
|
BRF
3
B. Riley Financial
Los Angeles,
California
| $1.13M | – | – | – |
|
|
4
Vanguard Group
Malvern,
Pennsylvania
| $528K | +$46.8K | +237 | +6% |
|
|
VC
5
Voss Capital
Houston,
Texas
| $446K | +$139K | +702 | +26% |
|
|
6
Ensign Peak Advisors
Salt Lake City,
Utah
| $307K | +$461K | +2,334 | New |
|
|
SPC
7
Sigma Planning Corp
Ann Arbor,
Michigan
| $126K | +$188K | +953 | New |
|
|
8
HighTower Advisors
Chicago,
Illinois
| $44K | +$65.7K | +333 | New |
|
9
BlackRock
New York
| $42K | +$1.78K | +9 | +3% |
|
|
TRCT
10
Tower Research Capital (TRC)
New York
| $14K | +$1.78K | +9 | +9% |
|
|
11
UBS Group
Zurich,
Switzerland
| $8K | -$11.3K | -57 | -50% |
|
12
Morgan Stanley
New York
| $8K | +$11.3K | +57 | +814% |
|
|
13
Tudor Investment Corp
Stamford,
Connecticut
| – | -$434K | -2,110 | Closed |
|
|
RCG
14
Rock Creek Group
Washington,
District of Columbia
| – | -$292K | -1,409 | Closed |
|
|
15
Millennium Management
New York
| – | -$175K | -845 | Closed |
|
INAB Hedge Fund Activity: Q4 2021 in Review
13 of the 6,498 institutional investors tracked by Wall St. Rank reported a position in IN8bio (INAB) for Q4 2021, worth a combined $7.8M — down 36% from $12.2M a quarter earlier.
Fund positioning in INAB was balanced in Q4 2021: 3 funds opened new positions, 3 closed out, 5 added to existing stakes and 2 trimmed.
The largest buyer was Ensign Peak Advisors, opening a new position worth an estimated $461K. The largest seller was Tudor Investment Corp, exiting entirely with an estimated $434K sold.
- 13 institutional investors held IN8bio (INAB) as of Q4 2021, unchanged from Q3 2021.
- Funds reported $7.8M of IN8bio stock for Q4 2021, down 36% quarter-over-quarter.
- 3 funds opened new IN8bio positions in Q4 2021 and 3 closed out, a net change of 0 holders.
- The largest IN8bio buyer in Q4 2021 was Ensign Peak Advisors, an estimated $461K added.
- The largest IN8bio seller in Q4 2021 was Tudor Investment Corp, an estimated $434K sold.
Based on aggregated 13F filings for Q4 2021.